Co-Authors
This is a "connection" page, showing publications co-authored by ANNA MALOVANNAYA and MEENAKSHI ANURAG.
Connection Strength
0.387
-
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2025 Nov 03; 15(11):2326-2343.
Score: 0.062
-
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
Score: 0.061
-
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses. bioRxiv. 2025 Jan 08.
Score: 0.059
-
Kinase inhibitor pulldown assay (KiP) for clinical proteomics. Clin Proteomics. 2024 Jan 16; 21(1):3.
Score: 0.055
-
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Res. 2023 10 02; 83(19):3237-3251.
Score: 0.054
-
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563.
Score: 0.053
-
Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532.
Score: 0.042